The stock of Nutex Health Inc. (NASDAQ:NUTX) increased by $0.01 on Tuesday to finish at $0.29, up 3.95 percent. The last five days have seen an average of 1,623,940 shares of common stock traded. 2 times new highs were reached in the current year, with a fall of -$1.6050. The average number of shares traded over the last 20 days was 1,537,325, while the average volume over the last 50 days totaled 2,399,288.
NUTX stock dropped -29.49% since last month. On 08/24/23, the company’s shares reached a one-month low of $0.2570. The stock touched a high of $4.05 on 01/04/23, after rallying from a low of $0.26 in 52 weeks. The price of NUTX stock has declined by -84.47% or -$1.6050 this year, reaching a new high 2 times. Still, the stock price is down -92.72% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
NUTX stock investors should be aware that Nutex Health Inc. (NUTX) stock had its last reported insider trading activity 76 days ago on Jun 15. On Jun 15, Chief Financial Officer Bates Jon Christian acquired 20,000 shares at $0.42 each. This transaction resulted in the insider spending $8,346. On Jun 14, Creem Mitchell added 50,000 shares at a price of US$0.43. After the transaction, the insider now owns 81,746 shares. Chief Legal Officer Montgomery Pamela W. had earlier bought 12,000 shares on Jun 14 for $0.43 a share. The transaction was completed for $5,141.
Valuation Metrics
Beta for the stock is 0.72. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 0.99, the price-to-book (PB) ratio of 2.11.
Financial Health
For the three months ended June 29, Nutex Health Inc.’s quick ratio was 1.80, while its current ratio was 1.90, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 2.66, and the total debt to equity ratio is 2.85. As far as profitability goes, gross margin for the trailing twelve months is -8.20% percent. Based on annual data, it had gross profit of $13.45 million and revenue of $219.29 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. There was a -122.70% return on investment (ROI) in the past year.
Earnings Surprise
According to Nutex Health Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $58.92 million, while revenues rose by 1.48% to $56.33 million. It was predicted that Nutex Health Inc.’s quarterly earnings would be -$0.01, but it ended up being $0. EBITDA was $3.8 million for the quarter. At the end of Nutex Health Inc.’s most recent quarter ended June 29, its liabilities totaled 328.01 million, while its total debt was $286.89 million. Equity owned by shareholders amounts to $661.9 million.
Technical Picture
Here’s a quick look at Nutex Health Inc.’s (NUTX) price momentum from a technical perspective. As of 29 August, the RSI 9-day stood at 38.77%, suggesting the stock is Neutral, with a 70.05% historical volatility rate.
The stochastic %K and %D were 20.72% and 16.84% respectively, while the average true range (ATR) was 0.0330. Based on the 14-day stochastic reading of 27.54%, the RSI (14) reading is 38.31%. On the 9-day MACD Oscillator, the stock is at -0.0103, and the 14-day reading is at -0.0275.
Analyst Ratings
In its analyst report released on February 22, 2023, Northland Capital began covering Nutex Health Inc. (NASDAQ: NUTX). The stock was rated as an Outperform by the brokerage firm. Analysts have assigned Nutex Health Inc. (NUTX) an Buy rating. NUTX is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 2 others recommend it as a buy.
What is NUTX’s price target for the next 12 months?
The current consensus forecast for the stock is between $2.50 and $3.00, with a median target price of $2.75. In analyzing these forecasts, the average price target given by analysts for Nutex Health Inc. (NUTX) is $2.75.
